Kramer H J, Uhl W, Ladstetter B, Bäcker A
Renal Section, Medical Policlinic, University of Bonn, Germany.
Br J Clin Pharmacol. 2000 Sep;50(3):227-35. doi: 10.1046/j.1365-2125.2000.00256.x.
The purpose of the study was to investigate the effects of asimadoline, a new kappa-opioid agonist, on renal function and on hormones related to body fluid balance as well as its tolerability in healthy subjects.
In a placebo-controlled, randomised, double-blind crossover design we studied the effects of single oral doses of 1, 5, and 10 mg of asimadoline, in 24 healthy volunteers. Two hour control urine collections were followed by 2 h postdose urine collections and subsequently 2.5% saline was given i.v. at a rate of 0.3 ml min(-1) kg(-1) during another 2 h urine collection. Blood was obtained hourly. Arginine-vasopressin (AVP), atrial natriuretic peptide (alpha-hANP), endothelin (ET-1) and cAMP were determined by r.i.a. or ELISA.
GC-MS measurements revealed Cmax values of asimadoline in plasma ranging from 18 ng ml(-1) at the 1 mg dose, 91 ng ml(-1) at the 5 mg dose, to 214 ng ml(-1) at the 10 mg dose after an average of 1.1-1.4 h. Without effects on blood pressure, heart rate, GFR or urine electrolyte excretion, urine volume increased after 1-2 h after administration of 5 and 10 mg asimadoline from 3.3+/-1.3 to 5.6+/-1.4 (P<0.05) and from 3.2 +/-1.6 to 5.5+/-2.2 ml min(-1) (P<0.01), respectively. CH2O rose from 0.2+/-1.5 to 2.0+/-1.6 (P<0.05) and from 0.6+/-1.6 to 3.0+/-1.6 ml min(-1) (P<0.01). Urinary excretion of AVP was suppressed only with the 10 mg dose from 46+/-23 to 25+/-15 fmol min(-1) (P<0.05) without and from 410+/-206 to 181+/-125 fmol min(-1) (P<0.05) with stimulation by 2.5% saline. Plasma AVP was suppressed only by the 10 mg dose of asimadoline in six of eight subjects during the 2.5% saline infusion. Changes in the alpha-hANP or ET-1 systems were not affected by asimadoline.
Asimadoline is diuretic in man after single doses of 5 or 10 mg probably through a direct effect at the renal tubular level. Suppression of AVP secretion was observed only at the highest dose level of 10 mg of asimadoline.
本研究旨在探讨新型κ阿片受体激动剂阿西马朵林对健康受试者肾功能、与体液平衡相关激素的影响及其耐受性。
在一项安慰剂对照、随机、双盲交叉设计中,我们研究了24名健康志愿者单次口服1、5和10mg阿西马朵林的效果。先进行2小时对照尿液收集,然后在给药后2小时收集尿液,随后在另外2小时尿液收集期间以0.3ml·min⁻¹·kg⁻¹的速率静脉输注2.5%盐水。每小时采集血液。通过放射免疫分析或酶联免疫吸附测定法测定精氨酸加压素(AVP)、心钠素(α-hANP)、内皮素(ET-1)和环磷酸腺苷(cAMP)。
气相色谱-质谱测量显示,阿西马朵林血浆Cmax值在1mg剂量时为18ng·ml⁻¹,5mg剂量时为91ng·ml⁻¹,10mg剂量时为214ng·ml⁻¹,平均在1.1 - 1.4小时后达到。在不影响血压、心率、肾小球滤过率或尿电解质排泄的情况下,给予5mg和10mg阿西马朵林后1 - 2小时尿量增加,分别从3.3±1.3增至5.6±1.4(P<0.05)和从3.2±1.6增至5.5±2.2ml·min⁻¹(P<0.01)。自由水清除率从0.2±1.5增至2.0±1.6(P<